-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Harmony Biosciences Hldgs, Lowers Price Target to $36

Benzinga·02/25/2026 19:53:01
Listen to the news
UBS analyst So Youn Shim maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Neutral and lowers the price target from $46 to $36.